NCT03166878 is a phase I/II study evaluating the efficacy and safety of UCART019 gene-edited allogeneic CD19-targeting CAR T cells in patients with relapsed or refractory CD19+ leukemia and lymphoma (273). Here, CD19 is linked to lymphoma.